<DOC>
	<DOC>NCT00908921</DOC>
	<brief_summary>To investigate the glycosylated hemoglobin (HbA1c) control of Glimepiride (AMARYL) as OAD initiation mono-therapy in type 2 diabetic patients in China.</brief_summary>
	<brief_title>Efficacy and Safety of Glimepiride as Oral Anti-Diabetic (OAD) Initiation Mono-therapy in Chinese Type 2 Diabetes Mellitus (T2DM)</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus, Type 2</mesh_term>
	<mesh_term>Glimepiride</mesh_term>
	<mesh_term>Hypoglycemic Agents</mesh_term>
	<criteria>Newly diagnosed T2DM and inadequately controlled with diet and exercise or T2DM diagnosed &lt;6 months and who had not taken oral antidiabetic medication or insulin for &gt;3months. HbA1C more than 7.5 and less than 11. Fasting plasma glucose of &gt;13.5mmol/L Type 1 Diabetes Mellitus (T1DM) Patient with acute illness hospitalized in last 2 months Patient with active liver disease, impaired renal or hepatic functions Known hypersensitivity to glimepiride, other sulfonylureas, other sulfonamides or any other excipients of AMARYL Pregnant and lactating women The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2012</verification_date>
</DOC>